+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07882472

Phase 1 Study Evaluating Safety and Pharmacokinetics of Single Intramuscular Doses of DTI-117 Compared to Placebo in Healthy Adults

Led by Dignify Therapeutics · Updated on 2026-10-26

40

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety, tolerability, and how the body processes DTI-117, a drug given by a single intramuscular injection, in healthy adult volunteers. This Phase 1 study uses a double-blind, placebo-controlled, randomized design with up to five groups of 8 participants each. The study focuses on healthy adults aged 18 to 65 years with no significant health problems. Participants receive a single intramuscular dose of DTI-117 at varying levels 0.03, 0.05, 0.1, 0.2, or 0.3 mgkg. Each dose group includes some participants who get a placebo injection of saline solution. The study is conducted sequentially, with careful monitoring after dosing to assess safety and drug levels in the body. During the study, participants undergo medical history reviews, physical exams, ECGs, lab tests, and monitoring of vital signs for up to seven days after dosing. Researchers measure adverse events, abnormal lab results, and heart activity. They also track drug levels in the blood at multiple time points after injection and monitor timing of urination and defecation within 24 hours. Total participation time covers screening through safety follow-up.

CONDITIONS

Brief Title

A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.

Research Team

E

Ed Burgard, PhD

K

Karl Thor, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here